|
Mutation Information
|
Mutation Site
|
A62A |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Relevant Drug
|
darunavir;cobicistat;emtricitabine (FTC);tenofovir alafenamide (TAF);tenofovir disoproxil fumarate (TDF) |
|
Country
|
USA |
Literature Information
|
PubMed PMID
|
31516033
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2020 |
|
Journal
|
AIDS research and human retroviruses |
|
Title
|
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. |
|
Author
|
Lathouwers E,Wong EY,Brown K,Baugh B,Ghys A,Jezorwski J,Mohsine EG,Van Landuyt E,Opsomer M,De Meyer S,AMBER and EMERALD Study Groups. |
|
Evidence
|
NNRTI and N(t)RTI RAMs were detected in HIV-1 of 16% and 5% of participants, respectively, with K103N and polymorphic E138E/A mutation being the most prevalent NNRTI RAMs (both 4%) and A62A/V (3%) the most prevalent N(t)RTI RAM (Table 1).
|
|
|
HIV Mutation Detail Information